Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR00007
|
|||||
Drug Name |
Prostaglandin f2Alpha
|
|||||
Synonyms |
Amoglandin; Cerviprost; Cyclosin; Enzaprost; PGF2alpha; Panacelan
|
|||||
Drug Type |
Small molecular drug
|
|||||
Indication | Solid tumours [ICD11:2D4Z] | Preclinical | [1] | |||
Structure |
|
![]() |
||||
3D MOL | 2D MOL | |||||
Formula |
C20H34O5
|
|||||
Canonical SMILES |
CCCCCC(C=CC1C(CC(C1CC=CCCCC(=O)O)O)O)O
|
|||||
InChI |
InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25)/b7-4-,13-12+/t15-,16+,17+,18-,19+/m0/s1
|
|||||
InChIKey |
PXGPLTODNUVGFL-YNNPMVKQSA-N
|
|||||
CAS Number |
CAS 551-11-1
|
|||||
Pharmaceutical Properties | Molecular Weight | 354.5 | Topological Polar Surface Area | 98 | ||
Heavy Atom Count | 25 | Rotatable Bond Count | 12 | |||
Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 5 | |||
XLogP |
2.7
|
|||||
PubChem CID | ||||||
PubChem SID |
103214323
,103943633
,104046437
,113853160
,124892254
,124892255
,125307573
,126662422
,134340899
,134978425
,135651540
,137006907
,142063920
,144205330
,14852168
,15398784
,162205063
,175268163
,175607780
,176484109
,179116866
,211534905
,223673680
,226412676
,26754609
,29216066
,3912
,39289529
,4265953
,47588758
,47588759
,48258963
,48415906
,50026801
,50110092
,53789218
,56311306
,56313004
,56313208
,57357710
,613198
,77668180
,7847149
,7980284
,8143215
,8616237
,92308787
,92309910
,99300824
,99302342
|
|||||
ChEBI ID |
CHEBI:15553
|
|||||
TTD Drug ID | ||||||
DT(s) Transporting This Drug | 1-Oct | Transporter Info | Organic cation transporter 1 | Substrate | [2] | |
2-Oct | Transporter Info | Organic cation transporter 2 | Substrate | [2] | ||
MRP4 | Transporter Info | Multidrug resistance-associated protein 4 | Substrate | [3] | ||
OAT1 | Transporter Info | Organic anion transporter 1 | Substrate | [2] | ||
OAT2 | Transporter Info | Organic anion transporter 2 | Substrate | [4] | ||
OAT3 | Transporter Info | Organic anion transporter 3 | Substrate | [2] | ||
OAT4 | Transporter Info | Organic anion transporter 4 | Substrate | [2] | ||
OATP2A1 | Transporter Info | Organic anion transporting polypeptide 2A1 | Substrate | [5] | ||
OATP3A1 | Transporter Info | Organic anion transporting polypeptide 3A1 | Substrate | [6] | ||
Drug-Transporter Activity Data | ||||||
Drug-Transporter Activity Data | 1-Oct | Transporter Info | Km =0.477 microM | Proximal tubule (S2) cells-OCT1 | [2] | |
2-Oct | Transporter Info | Km =0.344 microM | Proximal tubule (S2) cells-OCT2 | [2] | ||
OAT1 | Transporter Info | Km =0.575 microM | Proximal tubule (S2) cells-OAT1 | [2] | ||
OAT2 | Transporter Info | Km =0.425 microM | Proximal tubule (S2) cells-OAT2 | [4] | ||
OAT3 | Transporter Info | Km =1.092 microM | Proximal tubule (S2) cells-OAT3 | [2] | ||
OAT4 | Transporter Info | Km =0.692 microM | Proximal tubule (S2) cells-OAT4 | [2] | ||
References | ||||||
1 | Stereocontrolled organocatalytic synthesis of prostaglandin PGF2alpha in seven steps. Nature. 2012 Sep 13;489(7415):278-81. | |||||
2 | Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8. | |||||
3 | Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007. | |||||
4 | Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther. 2002 Jun;301(3):797-802. | |||||
5 | Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J Clin Invest. 1996 Sep 1;98(5):1142-9. | |||||
6 | Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1188-97. |
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.